Advertise on podcast: Clearly Hormonal

📱 Send Us a Text Message! We’d love to hear from you! Please include your name and email address so we can reply. Don’t worry — this won’t sign you up for our email list. We’ll only use your info to respond to your question. "Hormones cause breast cancer" is the sentence that keeps many women from even asking about hormone therapy. In episode three of our Menopause Awareness Month series, Dr. Komal Patil-Sisodia takes it apart using what the Women's Health Initiative really found, and shows why the real question is which hormone, for whom, for how long, and compared to what. You will hear who was actually studied, what the numbers mean in absolute terms, what the FDA label changes do and do not mean, and how body fat, screening, and breast density fit in, plus options for women with a breast cancer history. Whatever you decide, you deserve to make that decision with facts, not fear. Timestamps 00:00 | Welcome to Clearly Hormonal 01:03 | The fear statement 02:02 | Why this episode now 02:56 | WHI study context 04:39 | Two trials, two outcomes 06:31 | What the WHI missed 07:25 | FDA label changes 08:41 | Absolute risk numbers 10:35 | Four common myths 12:09 | Body fat and estrogen 14:03 | Screening and density 15:40 | High risk and survivors 17:28 | Key takeaways and what is next Thanks for listening. Find more info about Clearly Hormonal on the website or Instagram.

📱 Send Us a Text Message! We’d love to hear from you! Please include your name and email address so we can reply. Don’t worry — this won’t sign you up for our email list. We’ll only use your info to respond to your question. Your weight has not changed, but your body has. In this episode, Dr. Komal Patil-Sisodia explains why body composition shifts during the menopause transition, why the scale cannot tell the whole story, and what you can do about it. She shares her own experience after a hysterectomy, breaks down the difference between subcutaneous and visceral fat, explains insulin resistance with a classic TV analogy, and walks through a realistic foundation of strength, nutrition, sleep, and sustainable planning. She also covers where menopause hormone therapy and obesity medications fit, and why higher body fat after menopause is linked to breast cancer risk without placing blame on anyone. Clearly Hormonal is for education and is not personalized medical advice. Take what resonates and discuss it with your own healthcare team. IN THIS EPISODE Why you can gain fat and lose lean tissue without a big change on the scaleWhat body composition is, and why lean tissue is more than muscleWhat the SWAN study found about fat and lean mass during the menopause transitionWhy abdominal fat storage can shift before your periods stopOther contributors beyond hormones: aging, activity, sleep, stress, medications, and conditions like hypothyroidism, prediabetes, and insulin resistanceSubcutaneous versus visceral fat, and what a changing waist measurement may signalInsulin resistance explained, and why less muscle means less sugar used upStrength training at least twice a week, plus building toward 150 to 300 minutes of moderate activityProtein and fiber at meals, personalized protein needs, and why restriction is not the goalSleep, night sweats, sleep apnea, and when to ask about a sleep studyMenopause hormone therapy and body composition: what the evidence does and does not sayWhen obesity medications may be appropriateThe breast health connection, discussed without blameTIMESTAMPS 00:00 | Welcome to Clearly Hormonal 01:03 | PMOS Course Announcement 01:41 | Midlife Body Changes 03:41 | What Is Body Composition 05:03 | Hormones and Other Factors 06:59 | Visceral Fat and Waist 07:58 | Insulin Resistance Explained 10:59 | What Helps Most 11:06 | Strength and Movement 12:36 | Nutrition Basics 13:58 | Sleep and Barriers 15:25 | Hormone Therapy and Meds 18:11 | Breast Health Connection 19:01 | Key Takeaways and Next Week Course announcement The PMOS Conversation You Deserve is Dr. Komal’s patient course on understanding PMOS and advocating for yourself in the doctor’s office. It includes three months of access plus a monthly live Q&A webinar with Dr. Komal. Introductory pricing runs through October 13, with regular pricing beginning October 20. Monthly webinar calls begin October 21, 2026.  Details and enrollment: The Perimenopause Conversation You Deserve Connect Instagram and TikTok: @drpatilsisodiaWebsite: eastsidemm.comQuestions about the course: send a message through the website or DM on socialThanks for listening. Find more info about Clearly Hormonal on the website or Instagram.

📱 Send Us a Text Message! We’d love to hear from you! Please include your name and email address so we can reply. Don’t worry — this won’t sign you up for our email list. We’ll only use your info to respond to your question. Perimenopause is often missed because the most common symptom is vague (“I just don’t feel like myself”) and hormone tests can look normal. In this episode of Clearly Hormonal, Dr. Komal Patil-Sisodia walks through how perimenopause is actually recognized: from your age, your menstrual pattern, and your symptoms over time. This is Episode 1 of our Menopause Awareness Month series. In this episode you will learn Why a normal hormone result does not rule out perimenopauseThe three things Dr. Komal focuses on: age, periods, and symptomsHow cycles differ in early and late perimenopause, using the STRAW+10 frameworkWhat can make perimenopause harder to recognize: birth control, hysterectomy, and PMOS (formerly PCOS)Why FSH and estradiol are a snapshot, and when blood tests do helpWhy pregnancy testing should be one of the first tests if you miss a periodFour symptom groups: sleep, mood and thinking, physical comfort, and sexual and urinary healthOther conditions to rule out: thyroid disease, anemia, sleep apnea or insomnia, medication effects, and worsening anxiety or depressionWhat a useful perimenopause appointment includes, and how to prepare for itTimestamps 00:00 | Could This Be Perimenopause? 01:06 | Why Labs Miss It 02:16 | Three Diagnosis Clues 03:45 | Cycle Changes Explained 04:49 | Early vs. Late Transition 06:36 | When Cycles Mislead 07:32 | Hormone Testing Myths 08:50 | When Bloodwork Helps 10:12 | Symptom Categories 11:53 | Rule Out Other Causes 13:02 | Differences Across Women 15:38 | What a Good Visit Includes 16:52 | Three Key Takeaways 17:26 | Prep for Your Appointment 18:17 | Series Wrap and Course Announcement Course announcement The PMOS Conversation You Deserve is Dr. Komal’s patient course on understanding PMOS and advocating for yourself in the doctor’s office. It includes three months of access plus a monthly live Q&A webinar with Dr. Komal. Introductory pricing runs through October 13, with regular pricing beginning October 14. Monthly webinar calls begin October 21, 2026.  Details and enrollment: The Perimenopause Conversation You Deserve Connect Instagram and TikTok: @drpatilsisodiaWebsite: eastsidemm.comQuestions about the course: send a message through the website or DM on socialThanks for listening. Find more info about Clearly Hormonal on the website or Instagram.

📱 Send Us a Text Message! We’d love to hear from you! Please include your name and email address so we can reply. Don’t worry — this won’t sign you up for our email list. We’ll only use your info to respond to your question. About one in eight women lives with PMOS, polyendocrine metabolic ovarian syndrome, formerly called PCOS. It is one of the most common hormone conditions there is, and still one of the most misunderstood, by patients and by many clinicians. In this final episode of September PMOS Awareness Month, Dr. Komal Patil-Sisodia explains why the name changed, why the condition is about far more than ovarian cysts, and why the metabolic and cardiovascular pieces so often get missed when a visit stays focused on periods, acne, or hair growth. She also shares what the data shows about diagnosis delays and disparities, and a piece of her own story. Then she moves from the science to the practical: what to ask, what to track, and what to do when you raise a reasonable concern and do not get a useful answer. She introduces her new six-module course, The PMOS Conversation You Deserve, built to help you walk into your next appointment better informed and better prepared. IN THIS EPISODE Why PMOS stands for polyendocrine metabolic ovarian syndrome, and why the change from PCOS was more than a rebrandHow PMOS can show up across the lifespan, from adolescence through the reproductive years, perimenopause, and beyondThe metabolic side of PMOS: insulin resistance, blood sugar, cholesterol, blood pressure, and long-term cardiovascular riskWhat one large international study found about diagnostic delays: about one in three women waited more than two years, and nearly half saw at least three healthcare professionalsDisparities in who gets diagnosed, including findings in a safety net health system study for Black women and patients on Medicaid or charity careWhy knowing the science is not the same as knowing how to use it in an appointmentA first look at The PMOS Conversation You Deserve, including the pushback module, the workbook, and three months of live Q&ATIMESTAMPS 00:00  Welcome to Clearly Hormonal 01:08  PMOS: Why It Matters 02:22  PMOS Name Change Explained 02:57  Symptoms and Lifespan Impact 04:04  Diagnosis Delays and Disparities 05:51  Turning Knowledge Into Care 07:17  Course: The Conversation You Deserve 08:53  Enrollment Dates and Details 09:45  Final Takeaways and Wrap Up COURSE DATES Pre-order opens: October 7Introductory pricing through: October 13Regular price begins: October 14First live Q&A: October 21LINKS AND RESOURCES The PMOS Conversation You Deserve (pre-order opens October 7): Sign up here to get on the list.Eastside Menopause & Metabolism: eastsidemm.comFollow Dr. Patil-Sisodia on Instagram and TikTok: @drpatilsisodiaDISCLAIMER This podcast is for education and is not personalized medical advice. Please discuss what resonates with your own healthcare team. Thanks for listening. Find more info about Clearly Hormonal on the website or Instagram.

📱 Send Us a Text Message! We’d love to hear from you! Please include your name and email address so we can reply. Don’t worry — this won’t sign you up for our email list. We’ll only use your info to respond to your question. In the final episode of PMOS Awareness Month, I focus on something that does not get talked about enough: the mental health toll of PMOS and the harm caused by waiting years for a diagnosis. We walk through what weight-matched studies show about depression, anxiety, and eating disorders, why so many people carry these burdens long before anyone connects them to PMOS, and what real care should look like. In this episode Why people with PMOS are about four times more likely to have depression and more than five times more likely to have anxietyWhy a PMOS diagnosis often comes before a new diagnosis of depression, anxiety, or sleep problemsHow eating disorder risk rises with PMOS, and why it is not limited to larger bodiesHow years of scattered symptoms and "it is just stress" responses make things worseWhy body image distress from visible symptoms is a real pathway to disordered eatingWhat good care includes: screening at diagnosis, CBT as a first step, careful medication choices, treating physical symptoms, and mind-body approaches Timestamps 00:00 Welcome to Clearly Hormonal 01:01 PMOS Series Finale Setup 02:04 Mental Health Stats in PMOS 03:24 Eating Disorders and PMOS 04:00 Why Diagnosis Takes Years 05:37 Body Image and Visible Symptoms 06:56 What Good Care Looks Like 08:50 What This Means for You 09:51 Series Wrap Up and Resources 11:02 PMOS Mini Course Announcement Key numbers from the episode About 4 times more likely to have depression with PMOS, in weight-matched studiesMore than 5 times more likely to have anxiety with PMOSAbout 1 in 3 people with PMOS have moderate to severe depression; more than 4 in 10 have real anxiety symptoms; well under 15 percent without PMOSAbout 1.5 times more likely to have an eating disorder, with the biggest increases in binge eating disorder and bulimia The full PMOS Awareness Month series Episode 1: What happens in PMOS after your childbearing yearsEpisode 2: Why PMOS gets missed in people with a normal BMI (lean PMOS)Episode 3: Where GLP-1 medications fit into PMOS treatmentEpisode 4: PMOS and mental health (this episode) A note on support If anything in this episode brought up something personal for you, especially around food, body image, or how you have been feeling emotionally, please do not sit with that alone. Talk to your doctor or a mental health professional. If you are in crisis in the US, you can call or text 988 at any time. Connect Instagram and TikTok: @drpatilsisodiaeastsidemm.comThis episode is for education and is not a substitute for individual medical advice. Thanks for listening. Find more info about Clearly Hormonal on the website or Instagram.

📱 Send Us a Text Message! We’d love to hear from you! Please include your name and email address so we can reply. Don’t worry — this won’t sign you up for our email list. We’ll only use your info to respond to your question. Dr. Komal Patil-Sisodia, obesity advocate Michael Donnelly-Boylen, and Dr. Matthea Rentea explain why they withdrew from a planned ADA-hosted webinar in support of a broader boycott, after an ADA Scientific Sessions keynote by a MAHA representative and the removal of peacefully protesting scientists were followed by an organizational response the three of them found unsatisfying. They still share the content they had planned to present: integrating peer and lived experience into obesity care, to address a trust gap driven by weight stigma, shaming language, and oversimplified messaging that can delay or derail care, including preventive screening and procedures. They talk through curiosity, person-first language, motivational interviewing, and acknowledging medical trauma, along with practical solutions such as moderated peer support groups, credible online resources, and comprehensive programs that combine lifestyle foundations, medications, bariatric pathways, and clinic infrastructure shaped by patient input. Timestamps 00:00  Why This Episode Changed 00:47  ADA Boycott Context 02:15  Meet The Panel 03:26  Inside The Keynote Fallout 06:41  Protest And Conference Mood 10:01  Choosing To Withdraw 11:18  Webinar Topic And Roadmap 13:47  Trust Gap And Weight Stigma 18:37  Language That Builds Safety 23:23  Peer Support And Community 25:09  Social Media And Group Coaching 27:19  Why I Started Posting 28:43  Building a Comprehensive Program 30:32  Three Pathways of Care 33:32  Designing for Real Bodies 35:54  Practical Clinician Changes 37:48  Mountain Dew Lesson 41:30  Trauma and Safe Spaces 42:25  Peer Support Communities 44:20  Insurance and Advocacy 46:27  Fighting Wellness Misinformation 47:55  How to Build Support Groups 50:53  Wrap Up and Where to Find Us Connect Dr. Komal Patil-Sisodia: Instagram and TikTok @drpatilsisodia. Podcast: Clearly Hormonal. Dr. Matthea Rentea: Instagram, TikTok, and YouTube. Podcast: The Obesity Guide with Matthea Rentea, MD, at renteaclinic.com. Michael Donnelly-Boylen: Instagram and TikTok as Mike On A Mission. Podcast: Weight and Measure with Mike and Zach, at weightandmeasurepod.com. Thanks for listening. Find more info about Clearly Hormonal on the website or Instagram.

📱 Send Us a Text Message! We’d love to hear from you! Please include your name and email address so we can reply. Don’t worry — this won’t sign you up for our email list. We’ll only use your info to respond to your question. Dr. Komal Patil-Sisodia continues the PMOS Awareness Month series by walking through where GLP-1 medications, like semaglutide and tirzepatide, fit into PMOS treatment. She explains what GLP-1s actually do in the body, who is likely to benefit, who they are not built for, and why they are never a stand-alone treatment plan for PMOS. In This Episode What a GLP-1 is and the three main effects these medications have on the bodyWhy insulin resistance sits at the center of PMOS for so many patients, and how that connects to androgen levels and symptoms like acne and excess hair growthWho is the clearest fit for a GLP-1: patients with insulin resistance or higher body weight, and those who haven't seen enough improvement from metformin or lifestyle changes aloneWho GLP-1s are not built for: lean PMOS patients without insulin resistance, and anyone trying to conceive soonWhy GLP-1s only work well alongside lifestyle change, and the real risks of low protein and fiber intake while on these medicationsWhat a GLP-1 does not replace: ongoing metabolic monitoring, fertility treatment, and androgen-targeted treatments like birth control pills or spironolactoneThe four questions Dr. Patil-Sisodia asks herself before recommending a GLP-1 for a PMOS patient Timestamps 00:00 Podcast Intro01:01 Series Setup02:13 GLP-1 Basics02:45 Why It Matters03:28 Who Benefits04:32 Who Should Avoid05:27 Lifestyle and Safety06:15 What GLP-1s Don't Replace07:40 How I Decide08:29 Wrap Up and Next Week09:36 Mini Course Promo Links Mentioned Newsletter sign-up: eastsidemm.com/newsletterFollow Dr. Patil-Sisodia: @drpatilsisodia on Instagram and TikTokThanks for listening. Find more info about Clearly Hormonal on the website or Instagram.

📱 Send Us a Text Message! We’d love to hear from you! Please include your name and email address so we can reply. Don’t worry — this won’t sign you up for our email list. We’ll only use your info to respond to your question. Many people picture PMOS (polyendocrine metabolic ovarian syndrome, formerly known as PCOS) as a condition tied to weight gain. But the diagnostic criteria never mention body size at all, and a significant number of people with PMOS have a completely normal BMI. In part two of our PMOS Awareness series, Dr. Patil-Sisodia breaks down “lean PMOS”: what it looks like, why it is so often missed, and why the metabolic risk is just as real even when the outside doesn't show it. In This Episode Why PMOS became associated with a specific body type, and why that picture was never the diagnosis itselfThe three actual diagnostic criteria: irregular or anovulatory cycles, elevated androgens (DHEAS, testosterone), and polycystic ovarian morphology on ultrasoundWhat lean PMOS symptoms look like: irregular periods, acne, facial and body hair growth, scalp thinning“Normal weight obesity”: how insulin resistance and visceral fat can hide behind a normal-looking exteriorThe three-part pattern that causes lean PMOS to slip through the cracks in clinical practiceWhy an undiagnosed lean PMOS patient loses out on cardiometabolic monitoring, not just a menstrual explanationWhat needs to change: for clinicians, dropping body size as a screening filter; for patients, presenting symptoms as a pattern instead of one at a timeTimestamps 00:00 | Welcome to Clearly Hormonal 01:01 | Series Setup: Lean PMOS 02:09 | Why PMOS Has a Body Type 02:42 | Diagnosis Criteria, Not Weight 03:39 | Lean PMOS Symptoms 04:05 | Hidden Insulin Resistance 05:01 | Why Lean PMOS Gets Missed 06:51 | Why Diagnosis Matters 08:05 | What Should Change 09:24 | Wrap Up and Next Week 10:03 | Mini Course Announcement Coming up next week: Episode three of the series looks at treatment, including where GLP-1 medications and other weight management tools fit into PMOS care, and who they actually make sense for. Sign up for the newsletter at eastsidemm.com/newsletter, and follow along on Instagram or TikTok @drpatilsisodia. This podcast is for education, not personalized medical advice. Please discuss anything you hear here with your own healthcare team. Thanks for listening. Find more info about Clearly Hormonal on the website or Instagram.

📱 Send Us a Text Message! We’d love to hear from you! Please include your name and email address so we can reply. Don’t worry — this won’t sign you up for our email list. We’ll only use your info to respond to your question. PMOS Awareness Month kicks off with a reframe: PMOS is not a condition that resolves once your cycles regulate or once you're done having kids. It is a lifelong cardiometabolic condition that happens to announce itself first through reproductive symptoms. Dr. Komal Patil-Sisodia walks through the three diagnostic criteria (irregular periods, high androgens, and polycystic ovarian morphology) and explains why the biology underneath, insulin resistance, visceral fat, and unfavorable cholesterol, persists even when periods look normal. She unpacks what worsens in perimenopause, the clinical blind spot that causes PMOS histories to get dropped from the chart, and what she actually changes in her own practice: earlier and trend-based lab monitoring, a shift in treatment goals from fertility to long-term metabolic and heart protection, and more individualized hormone therapy decisions. In This Episode Why the three PMOS diagnostic criteria are not the whole diseaseThe underlying biology: insulin resistance, visceral fat, and cholesterol changes that often start in the teenage yearsWhat worsens at perimenopause: insulin resistance, LDL and triglycerides, and belly fatThe missed clinical question that keeps PMOS histories from shaping midlife careWhy 20+ years of a less favorable metabolic starting point matters for heart disease riskWhat changes in practice: trend-based monitoring, shifting treatment goals, and individualized hormone therapyA preview of the rest of the PMOS Awareness Month seriesTimestamps 00:00 — Welcome to Clearly Hormonal01:03 — PMOS Beyond Fertility02:14 — PMOS Is Lifelong04:05 — Perimenopause Metabolic Shifts06:17 — The Missed Clinical Question07:52 — Heart Risk Over Decades09:38 — What To Do In Practice11:34 — Key Takeaways & Next Episodes12:46 — Mini Course InvitationComing Up in This Series Episode 2 — Lean PMOS (sometimes called "skinny PMOS") and why it gets missedEpisode 3 — Where GLP-1s and other weight management tools fit into PMOS careEpisode 4 — The long road to diagnosis and its toll on mental healthLinks Join the email list for the PMOS mini-course: eastsidemm.com/newsletterThanks for listening. Find more info about Clearly Hormonal on the website or Instagram.

📱 Send Us a Text Message! We’d love to hear from you! Please include your name and email address so we can reply. Don’t worry — this won’t sign you up for our email list. We’ll only use your info to respond to your question. On Women's Equality Day, host Dr. Komal Patil-Sisodia revisits an idea from an early episode of Clearly Hormonal: the menopause penalty, the disproportionate income loss, leadership attrition, and career disruption that midlife women face. This episode goes past the data to ask what it actually feels like to lead through sleep disruption, cognitive overload, and hormonal change while carrying the weight of an executive role. Guest Dr. Brooke Buckley traces her path from a punishing early surgical practice through hospital operations, an MBA negotiated into her first CMO contract, and a system-level leadership role she stepped into during the pandemic. She speaks candidly about infertility and loss, being the only woman in her surgical residency class, and the coaching and community that carried her through. The conversation moves into trauma-informed leadership, why physiology cannot be negotiated away, and the hard pivot Buckley made in walking away from the operating room to protect her own health. Audio Stamps00:00  Why Equality Still Lags 01:48  The Menopause Penalty 02:34  Meet Dr. Brooke Buckley 04:04  From Surgeon to Executive 07:32  Lessons From Organized Medicine 11:44  Midlife Friction and Storytelling 15:13  Boundaries as Superpower 18:07  Leading Through the Pandemic 21:29  Community, Coaching, and Accountability 27:20  Trauma-Informed Leadership 32:07  AI, Physiology, and the Future of Work 35:05  Hard Pivots and Closing Takeaways Guest BioDr. Brooke Buckley is a board-certified general surgeon and physician executive, board-certified in lifestyle medicine, and currently serves as System Vice President of Medical Affairs for Henry Ford Health. She previously served as chief medical officer and holds an MBA from Johns Hopkins. She has held national leadership roles with the American Hospital Association and The Joint Commission and is a widely followed voice on physician wellness, trauma-informed leadership, and healthcare system transformation. Instagram: play_your_story Thanks for listening. Find more info about Clearly Hormonal on the website or Instagram.

📱 Send Us a Text Message! We’d love to hear from you! Please include your name and email address so we can reply. Don’t worry — this won’t sign you up for our email list. We’ll only use your info to respond to your question. Two women get the same diagnosis, PMOS (formerly known as PCOS), and end up with completely different symptoms. One has irregular periods, acne, and high androgens. The other has none of that, just an ultrasound finding. How can that be the same condition? In this episode, Dr. Komal Patil-Sisodia breaks down the Rotterdam criteria, the three features used to diagnose PMOS, and explains why you only need two of the three to qualify. That single fact is the reason PMOS shows up as four distinct phenotypes (A, B, C, and D), each with its own symptom pattern and metabolic risk profile. You'll learn: What hyperandrogenism, ovulatory dysfunction, and polycystic ovarian morphology actually mean (without the jargon)The four PMOS phenotypes and which one carries the highest, and lowest, metabolic riskWhy insulin resistance, not BMI, may be the real driver of your riskWhy phenotype D ("the mild one") still deserves your attentionThree questions to bring to your next appointment to get more personalized careWhether you were diagnosed years ago or are newly navigating a PMOS diagnosis, this episode gives you language to better understand your own body, and better questions to ask the people caring for it. Audio Stamps: 00:00 Welcome to Clearly Hormonal 01:03 Why PMOS Looks Different 02:43 Rotterdam Criteria Explained 05:15 Phenotype A: Full House 06:03 Phenotypes B Through D 08:27 Why Phenotype Matters 11:00 Phenotype D Still Counts 12:44 Three Takeaways and Next Steps 14:39 Recap and Final Message This podcast is for educational purposes only and is not a substitute for personalized medical advice. Please discuss your own care with your healthcare team. Thanks for listening. Find more info about Clearly Hormonal on the website or Instagram.

📱 Send Us a Text Message! We’d love to hear from you! Please include your name and email address so we can reply. Don’t worry — this won’t sign you up for our email list. We’ll only use your info to respond to your question. Perimenopause is having a cultural moment, and endocrinologist Dr. Komal Patil-Sisodia is glad it is, but in this launch episode of Clearly Hormonal, she pushes back on social media's habit of attributing nearly any midlife symptom to hormones. She defines perimenopause as the years leading up to menopause (recognized after 12 months without a period, average age ~51) and explains that it's marked by hormonal variability, not simply “low estrogen,” with menstrual-cycle changes serving as an important clinical clue. She walks through why most women don't need single-point hormone testing, since levels fluctuate day to day, per current ACOG guidance. Using a composite patient example (“Jen”), she shows how fatigue, sleep issues, hair loss, and weight gain may reflect iron deficiency, thyroid disease, sleep apnea, nutrition, stress, medications, or life changes, not hormones by default. She closes with a four-question framework for sorting it out: where you are in the reproductive transition, whether a symptom is plausibly related to it, what else could explain it, and whether treating perimenopause would actually help. Taking symptoms seriously, she argues, requires evidence and continued curiosity, not a single convenient explanation. Timestamps 00:00  Welcome to Clearly Hormonal 01:03  Perimenopause Everywhere 01:32  Why Nuance Matters 03:24  How Social Media Shaped It 05:22  Defining Perimenopause 07:51  Hormone Testing Reality 09:29  Patient Example: Jen 11:51  Fatigue and Weight Gain 13:58  Brain Fog and Mood 15:35  Hair, Sleep, Libido, Joints 18:54  When “It's Just Perimenopause” Becomes a Problem 21:38  The Four-Question Framework 23:33  Key Takeaways and Invite 25:26  Quick Question: 3 AM Wakeups Key Takeaways Perimenopause is hormonal variability, not simply low estrogen: levels fluctuate rather than steadily decline in the early transition.Menopause is recognized after 12 consecutive months without a period; average age in the U.S. is around 51.Most women don't need a single hormone test to identify perimenopause: age, symptoms, and menstrual changes usually tell us more (ACOG).Common midlife symptoms (fatigue, weight change, hair loss, brain fog, mood shifts, low libido, joint pain) can have multiple causes beyond hormones.The four-question framework: (1) Where am I in the reproductive transition? (2) Is this symptom plausibly related to perimenopause? (3) Is there another explanation to consider? (4) Would treating perimenopause actually improve it?Taking a symptom seriously and attributing it to hormones by default are not the same thing.Resources & Links ACOG: Do I need to have testing of my hormone levels during perimenopause? (acog.org)Follow along: Instagram & TikTok @drpatilsisodiaGot a question for “Is This Actually Hormonal?”: DM @drpatilsisodia or send a note through the show's fan mail link.Thanks for listening. Find more info about Clearly Hormonal on the website or Instagram.

📱 Send Us a Text Message! We’d love to hear from you! Please include your name and email address so we can reply. Don’t worry — this won’t sign you up for our email list. We’ll only use your info to respond to your question. Endocrinologist Dr. Komal Patil-Sisodia defines peptides as short amino-acid chains (with examples like insulin) and notes that any package or claim stating “contains peptides” is meaningless without knowing which peptide, how it was tested, and what it's proven to do. She outlines the FDA approval pathway from preclinical work through Phase 1–3 trials and FDA review, then lists the FDA-approved peptides she prescribes for metabolic health (insulin analogs, GLP-1/GIP agents, glucagon, pramlintide), osteoporosis and calcium disorders (teriparatide, abaloparatide, palopegteriparatide, calcitonin), and reproductive/pituitary conditions (GnRH agonists, somatostatin analogs, vasopressin/desmopressin, cosyntropin, setmelanotide, bremelanotide). She contrasts these with trending “gray market” peptides (e.g., BPC-157, TB-500, GHK-Cu), noting most lack published peer-reviewed randomized human trials and are often sold as “research chemicals” without purity oversight. Her key filter: ask what high-quality human evidence supports a claim — emphasizing informed choices, doctor-guided decisions, and evidence over hype. In This Episode What a peptide actually is — and why the word alone doesn't mean anythingThe FDA's Phase 1–3 approval pathway, explained in plain languageThe full list of FDA-approved peptides Dr. Patil-Sisodia prescribes, organized by conditionWhy trending “gray market” peptides like BPC-157, TB-500, and GHK-Cu haven't cleared that same evidence barThe backlash from a recent social post — and what it revealed about asking for sourcesThe one question to ask before trying any new treatmentTimestamps 00:00 | Welcome to Clearly Hormonal 01:03 | Peptides Everywhere Now 01:51 | Peptides Explained Simply 02:47 | How FDA Approval Works 05:13 | Peptides I Prescribe 08:42 | Social Media Peptide Hype 10:43 | My Viral Post Backlash 12:53 | Spotting Real Evidence 13:46 | Final Takeaways and Wrap Connect Practice: eastsidemm.comInstagram & TikTok: @drpatilsisodiaThanks for listening. Find more info about Clearly Hormonal on the website or Instagram.

📱 Send Us a Text Message! We’d love to hear from you! Please include your name and email address so we can reply. Don’t worry — this won’t sign you up for our email list. We’ll only use your info to respond to your question. Dr. Komal Patil-Sisodia explains that headlines claiming “FDA approves peptides” are misleading: an FDA advisory committee narrowly voted to recommend adding six peptides (BPC-157, TB-500, KPV, MOTS-c, Epitalon, Semax) to a compounding list, a step that is not FDA approval and still faces a formal FDA process. She notes FDA scientists opposed adding all six and that some voting members sell these peptides. Reviewing the evidence, she explains that BPC-157 has only three small, weak human studies; TB-500 has zero human trials for the injury uses it's marketed for (while full thymosin beta-4 has some real human data); KPV has no human studies at all; MOTS-c has an unpublished Phase 1b trial and only observational, exercise-related human data; Epitalon lacks Western peer-reviewed human trials; and Semax is approved in Russia but with limited-quality stroke data. She emphasizes that all six are synthetic despite being marketed as "natural," that marketing to midlife women is running well ahead of the evidence, that contamination and mislabeled dosing have been documented in online peptide products, that compounded drugs bypass typical FDA review, and that proven options already exist for symptoms like hot flashes, bone loss, and metabolic changes. Time Stamps: 00:00  Welcome to Clearly Hormonal 01:03  The FDA Vote Explained 03:09  BPC-157 Evidence Check 04:31  TB-500 vs. Thymosin Beta-4 06:01  KPV and Animal Data Limits 07:25  MOTS-c, Epitalon, Semax 11:32  Midlife Marketing Reality 13:37  What the List Means 14:23  Safety and Contamination Risks 16:06  Bottom Line and Next Steps 17:31  Wrap Up and Where to Follow Resources & Mentions Follow Dr. Patil-Sisodia on Instagram and TikTok: @drpatilsisodiaJAMA: “Under FDA, Unapproved Peptides Likely to Become More Widely Available” (Rita Rubin, MA, 2026)ABC News: “FDA advisers narrowly vote to add 6 peptides to a drug compounding list. What's next?” (July 24, 2026)Talanta (2018): impurity analysis of falsified peptide drugs seized from online pharmaciesExpert Opinion on Drug Safety (2026): FAERS pharmacovigilance study on compounded GLP-1 receptor agonistsJournal of Cellular and Molecular Medicine (2021): Phase I dose-escalation trial of recombinant human thymosin beta-4Zhurnal Nevrologii I Psikhiatrii (2018): Semax post-stroke rehabilitation studyThanks for listening. Find more info about Clearly Hormonal on the website or Instagram.

📱 Send Us a Text Message! We’d love to hear from you! Please include your name and email address so we can reply. Don’t worry — this won’t sign you up for our email list. We’ll only use your info to respond to your question. Type 1 diabetes isn't just a childhood disease, and it isn't caused by sugar, weight, or lifestyle. In this episode, Dr. Komal Patil-Sisodia breaks down why type 1 diabetes is so often missed in adults, especially in people mislabeled as type 2, and introduces LADA (latent autoimmune diabetes in adults), a slow-moving form of type 1 that may account for up to a quarter of adult diagnoses. She walks through the clues that should prompt testing, the two blood tests that can change a diagnosis, and how perimenopause and menopause complicate blood sugar control for women living with type 1. The episode also covers pregnancy planning, the real (and often overstated) genetic risk to children, the underappreciated heart disease risk in women with type 1, and why needing insulin is never a sign of failure. In This Episode Why type 1 diabetes has nothing to do with sugar, weight, or lifestyleHow adult-onset type 1 gets misdiagnosed as type 2, and whyLADA (type 1.5): what it is and why it hides in plain sightThe clues that should prompt a GAD antibody and C-peptide testHow perimenopause and menopause make blood sugar harder to controlPregnancy with type 1 diabetes: what's actually trueThe real genetic risk to children (it's lower than you think)Why heart disease risk is elevated and underdiscussed in women with type 1Why insulin is not a “last resort” and never a sign you did something wrongThe technology (CGMs and automated insulin delivery) changing type 1 care Timestamps: 00:00   Why Type 1 Gets Missed 00:30   A Misdiagnosed Patient Story 02:52   Myth: Sugar Causes Type 1 05:31   Myth: Only Kids Get It 06:29   Adult Onset and the Honeymoon Period 08:41   LADA (Type 1.5) Explained 10:13   Perimenopause Makes It Harder 11:53   When to Test for Type 1 14:34   Pregnancy Myths and Facts 16:41   Heart Risk in Women 18:24   Insulin Shame and Stigma 20:44   Tech That Changed Diabetes Care 22:01   Perimenopause Management Tips 22:49   Key Takeaways and Next Steps 25:14   Final Thoughts and Share Resources Mentioned: GAD antibody test (glutamic acid decarboxylase antibody): the key immune marker for LADAC-peptide test: measures how much insulin your body is still producing on its ownContinuous glucose monitors (CGMs) and automated insulin delivery systemsMaternal-fetal medicine (perinatology) preconception counseling for planned pregnancies Disclaimer:  This podcast is for education, not personalized medical advice. Please discuss anything that resonates with your own healthcare team. Thanks for listening. Find more info about Clearly Hormonal on the website or Instagram.